20
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T16161 |
Mutant IDH1 inhibitor
|
Dehydrogenase; Isocitrate Dehydrogenase (IDH) | Metabolism |
Mutant IDH1 inhibitor 是一种突变型IDH1 R132H 的抑制剂,IC50<72 nM。 | |||
T2043 |
Mutant IDH1-IN-1
IDH1-IN-1 |
Dehydrogenase; Isocitrate Dehydrogenase (IDH) | Metabolism |
Mutant IDH1-IN-1 是 IDH1突变体的选择性抑制剂,能够作用于突变体 IDH1 R132C/R132C (IC50:4 nM) ,IDH1 R132H/R132H (IC50:42 nM) ,IDH1 R132H/WT (IC50:80 nM) 和野生型 IDH1 (IC50:143 nM)。 | |||
T12128 |
Mutant IDH1-IN-2
|
Isocitrate Dehydrogenase (IDH) | Metabolism |
Mutant IDH1-IN-2是突变型异柠檬酸脱氢酶蛋白抑制剂, 在荧光生物化学检测中IC50为16.6 nM,LS-MS 生物化学检测中IC50为<22 nM,。 | |||
T15551 | IDH889 | Dehydrogenase | Metabolism |
IDH889 是可口服有效的,脑渗透性的,变构和突变特异性的异柠檬酸脱氢酶抑制剂,对 IDH1 R132* 突变型具有高效选择性。它高效抑制细胞内 2-HG 水平,IC50为 0.014 μM。 | |||
T15550 |
IDH-305
|
Dehydrogenase | Metabolism |
IDH-305 是突变选择性的、口服性的、脑渗透性的 IDH1抑制剂,靶向 IDH1 (R132) 突变。它对突变体 IDH1 亚型的选择性比野生型高 200 倍 (IC50= 27 nM (IDH1R132H), 28 nM (IDH1R132C), 6.14 µM (IDH1WT))。 | |||
TQ0042 |
BAY-1436032
|
Dehydrogenase; Isocitrate Dehydrogenase (IDH) | Metabolism |
BAY-1436032 是一种选择性泛突变异柠檬酸脱氢酶 1 新型口服抑制剂。 | |||
T16384 |
Olutasidenib
FT-2102 |
Dehydrogenase; Isocitrate Dehydrogenase (IDH) | Metabolism |
Olutasidenib (FT-2102) 是一种可透过血脑屏障的、具有口服活性的、突变型异柠檬酸脱氢酶(IDH)1的选择性有效抑制剂,对IDH1- R132H 和 IDH1- R132C 的IC50分别为 21.2 nM 和 114 nM,可用于急性髓性白血病或骨髓增生异常综合征的研究。 | |||
T11612 |
IDH1 Inhibitor 3
|
Others | Others |
IDH1 Inhibitor 3 is a mutant isocitric dehydrogenase 1 (IDH1) inhibitor (IC50: 45 nM for IDH1R132H). | |||
T12129 | Mutant IDH1-IN-4 | Others | Others |
Mutant IDH1-IN-4 is an mutant Isocitrate dehydrogenase 1 (IDH 1) inhibitor. | |||
T62725 |
IDH1 Inhibitor 5
|
||
IDH1 Inhibitor 5 (compound 2) 是一种 IDH1(异柠檬酸脱氢酶 1)的抑制剂。IDH1 Inhibitor 5 能够抑制 MOG 细胞 (IC50: 64.4 nM) 以及表达外源突变 IDH1 R132H 蛋白的野生型 IDH1 胶质瘤细胞 (IC50: 34.9 nM)。 | |||
T70890 |
ML309
|
||
ML309 is a potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells. ML309 is capable of potent and selective inhibition of mutant IDH1 and effectively lowers cell-based production of 2-HG in a U87MG mutant glioblastoma cell line. | |||
T11613 |
IDH1 Inhibitor 1
|
Others | Others |
IDH1 Inhibitor 1 is an orally bioavailable, brain-penetrant, and selective mutant IDH1 inhibitor (IC50s: 0.021 μM, 0.045 μM, and 2.52 μM for IDH1R132H, IDH1R132C, and IDH1WT). | |||
T15442 |
GSK864
|
Others | Others |
GSK864 is an inhibitor of isocitrate dehydrogenase 1 (IDH1) mutant. GSK864 inhibits IDH1 mutants R132C, R132H, and R132G (IC50: 8.8, 15.2, and 16.6 nM). | |||
T63403 | WT IDH1 Inhibitor 2 | ||
WT IDH1 Inhibitor 2 是一种野生型异柠檬酸脱氢酶1 (WT IDH1) 抑制剂 (IC50: 120 nM),是突变体R132H IDH1抑制剂,是 GSK321 的异构体,具有野生型交叉反应性。 | |||
T63778 |
Safusidenib
|
||
Safusidenib 是选择性的、口服具有活力的 IDH1 突变型抑制剂,对突变型 IDH1 具有显著抑制作用,但不能抑制野生型 IDH1,能够抑制软骨肉瘤中的肿瘤活性。Safusidenib 对IDH1R132H 和 IDH1R132C 具有活性,在没有预孵育的情况下,IC50 值分别为 15 和 130 nM。 | |||
T32009 |
GSK321
GSK 321,GSK-321 |
||
GSK321 is an effective and selective IDH1 mutation inhibitor, which can effectively inhibit the production of 2-HG in HT-1080 cells, and induce IDH1 mutant cells to differentiate into bone marrow at the level of leukemia blasts and more stem cells. | |||
T38004 |
ML-309 (hydrochloride)
|
||
ML-309 is an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). It reversibly and selective inhibits IDH1R132H over wild-type IDH1 (IC50s = 96 and 36,500 nM, respectively). ML-309 reduces 2-hydroxyglutarate production in U87 MG glioblastoma cells (EC50 = 55 nM). | |||
T63402 |
(S,R)-WT IDH1 Inhibitor 2
|
||
(S,R)-WT IDH1 Inhibitor 2 是选择性的、有效的突变型 IDH1抑制剂,能够抑制 R132G (IC50: 2.9 nM)、R132C (IC50: 3.8 nM)、R132H (IC50: 4.6 nM) 和 WT IDH1 (IC50: 46 nM),选择性比 IDH2 高出 100 倍。(S,R)-WT IDH1 Inhibitor 2 具有诱导细胞内 2-HG 减少,髓细胞分化阻滞失效的作用,并且在白血病母细胞和更不成熟的干细胞水平诱导粒细胞分化,可研究用于急性髓系白血病 (AML) 及其他癌症。 | |||
T62698 | mIDH1-IN-1 | ||
mIDH1-IN-1 (compound 43) 是一种有效的、选择性的 mIDH1 (异柠檬酸脱氢酶 1 突变体) 抑制剂 (IC50: 961.5 nM)。mIDH1-IN-1 可以有效抑制 HT1080 细胞内 2-HG (2-hydroxyglutarate) 的产生 (EC50: 208.6±8.0 nM)。mIDH1-IN-1 对 IDH1 突变体 U-87 细胞表现出明显的抗增殖效果(IC50: 41.8 nM)。mIDH1-IN-1 是一种抗肿瘤剂,能够用于研究 IDH1 突变实体瘤。 | |||
T78758 |
IHMT-IDH1-053
|
Isocitrate Dehydrogenase (IDH) | Metabolism |
IHMT-IDH1-053(compound 16)为高选择性不可逆IDH1R132H突变抑制剂,IC50值仅为4.7 nM。对IDH1wt和IDH2wt/突变体活性低。该化合物在IDH1R132H突变293T细胞中显著抑制2-羟基戊二酸(2-HG)生成,IC50为28 nM。IHMT-IDH1-053通过与IDH1R132H蛋白的Cys269残基形成共价键,结合至NADPH结合袋附近的变构袋。此外,它能够抑制携带IDH1R132突变的HT1080细胞系及原代AML细胞增殖。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T83133 | Alternaphenol B2 | Isocitrate Dehydrogenase (IDH) | Metabolism |
IDH1 Inhibitor 是一种化学化合物,其通过选择性抑制异柠檬酸脱氢酶1 (IDH1) 酶的活性来起作用。这种抑制剂对R132突变的IDH1酶特别有效,因此在某些类型的癌症治疗中具有潜在的应用价值。IDH1 Inhibitor能够阻断异常的代谢途径和纠正肿瘤细胞增殖的代谢异常。在药物研发和临床试验中,研究人员评估其对特定肿瘤生长的抑制效果及其安全性和耐受性。 |